VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
Newly renamed Flagship Pioneering has raised a $285m venture capital fund to remain invested in portfolio companies as they grow. Also, 12 new and growing biopharma companies raised $657.15m.
You may also be interested in...
Tenaya is working on three separate approaches (gene therapy, cell therapy and small molecule) to develop new treatments for heart disease.
Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.
Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.